Abstract

The FDA has approved sotagliflozin (Inpefa – Lexicon), an oral sodium-glucose cotransporter 1 and 2 (SGLT1/2) inhibitor, to reduce the risk of hospitalization for heart failure (HF), urgent HF visits, and cardiovascular death in adults with either HF (with any left ventricular ejection fraction [LVEF]) or type 2 diabetes, chronic kidney disease (CKD), and other cardiovascular risk factors.

Full Text

Published Version
Open DOI Link

Topics from this Paper

  • Ejection Fraction
  • Death In Adults
  • Heart Failure
  • Chronic Kidney Disease
  • Cardiovascular Risk Factors
    • + Show 5 more

Create a personalized feed of these topics

Get Started

Get access to 115M+ research papers

Discover from 40M+ Open access, 2M+ Pre-prints, 9.5M Topics and 32K+ Journals.

Sign Up Now! It's FREE

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Systolic Dysfunction Portends Increased Mortality among Those Waiting for Renal Transplant
  • Journal of the American Society of Nephrology
  • Jun 1, 2008
Relevant
Not Relevant
Anemia of cardiorenal syndrome
  • Kidney International Supplements
  • Apr 1, 2021
Relevant
Not Relevant
Usefulness of Oral Ferric Citrate in Patients With Iron-Deficiency Anemia and Chronic Kidney Disease With or Without Heart Failure
  • The American Journal of Cardiology
  • Aug 1, 2018
Relevant
Not Relevant
Heart Failure and Diabetes Mellitus: Defining the Problem and Exploring the Interrelationship
  • The American Journal of Cardiology
  • Dec 1, 2019
Relevant
Not Relevant
Prognostic value of echocardiography for heart failure and death in adults with chronic kidney disease
  • American Heart Journal
  • Jun 1, 2022
Relevant
Not Relevant
Sodium–glucose cotransporter 2 inhibitors: A drug with antidiabetic and cardioprotective properties
  • Journal of Diabetes Investigation
  • Oct 22, 2020
Relevant
Not Relevant
Medical Costs of Chronic Kidney Disease and Type 2 Diabetes Among Newly Diagnosed Heart Failure Patients With Reduced, Mildly Reduced, and Preserved Ejection Fraction
  • The American Journal of Cardiology
  • Jul 1, 2023
Relevant
Not Relevant
Worsening Heart Failure Episodes Outside a Hospital Setting in Heart Failure with Preserved Ejection Fraction: The PARAGON-HF Trial.
  • Jacc-Heart Failure
  • Apr 2, 2021
Relevant
Not Relevant
Relation of Baseline Systolic Blood Pressure and Long-Term Outcomes in Ambulatory Patients With Chronic Mild to Moderate Heart Failure
  • The American Journal of Cardiology
  • Apr 1, 2011
Relevant
Not Relevant
POSTER PRESENTATIONS
  • Pacing and Clinical Electrophysiology
  • Nov 1, 2011
Relevant
Not Relevant
Intensity of Guideline-Directed Medical Therapy for Coronary Heart Disease and Ischemic Heart Failure Outcomes
  • The American Journal of Medicine
  • May 1, 2021
Relevant
Not Relevant
Worsening HeartFailure Episodes Outside a Hospital Setting in HeartFailure With Preserved Ejection Fraction: The PARAGON-HF Trial.
  • JACC. Heart failure
  • May 1, 2021
Relevant
Not Relevant
Recognizing Pregnancy-Associated Cardiovascular Risk Factors
  • The American Journal of Cardiology
  • Jan 1, 2014
Relevant
Not Relevant
Circulation Editors’ Picks
  • Circulation
  • May 14, 2013
Relevant
Not Relevant
Worsening Heart Failure Episodes Outside a Hospital Setting in Heart Failure With Preserved Ejection Fraction
  • JACC: Heart Failure
  • May 1, 2021
Relevant
Not Relevant
READ MORE FROM

The Medical letter on drugs and therapeutics

Sulbactam/durlobactam (Xacduro) for Acinetobacter pneumonia.
Just Published
  • The Medical letter on drugs and therapeutics
  • Nov 27, 2023
Relevant
Not Relevant
Shockwave therapy for erectile dysfunction.
Just Published
  • The Medical letter on drugs and therapeutics
  • Nov 27, 2023
Relevant
Not Relevant
In brief: GI effects of GLP-1 receptor agonists.
Just Published
  • The Medical letter on drugs and therapeutics
  • Nov 27, 2023
Relevant
Not Relevant
Ritlecitinib (Litfulo) for severe alopecia areata.
Open Access
Just Published
  • The Medical letter on drugs and therapeutics
  • Nov 27, 2023
Relevant
Not Relevant
Addendum.
Just Published
  • The Medical letter on drugs and therapeutics
  • Nov 27, 2023
Relevant
Not Relevant
Etrasimod (Velsipity) for ulcerative colitis.
Open Access
Just Published
  • The Medical letter on drugs and therapeutics
  • Nov 27, 2023
Relevant
Not Relevant
COVID-19 update: New Novavax vaccine formulation for 2023-2024.
  • The Medical letter on drugs and therapeutics
  • Nov 13, 2023
Relevant
Not Relevant
Correction.
  • The Medical letter on drugs and therapeutics
  • Nov 13, 2023
Relevant
Not Relevant
In brief: Empagliflozin (Jardiance) for chronic kidney disease.
  • The Medical letter on drugs and therapeutics
  • Nov 13, 2023
Relevant
Not Relevant
Antiviral drugs for influenza for 2023-2024.
  • The Medical letter on drugs and therapeutics
  • Nov 13, 2023
Relevant
Not Relevant